sarscov
caus
acut
infect
make
target
passiv
immunotherapi
attract
treatment
strategi
previous
gener
human
mab
specif
region
sarscov
protein
mab
bind
epitop
within
receptor
bind
domain
rbd
upstream
rbd
show
mab
recogn
epitop
within
rbd
inhibit
infect
prevent
viral
attach
cellular
receptor
one
mab
bind
upstream
rbd
prevent
viral
entri
inhibit
postbind
event
evalu
sever
mab
demonstr
vari
abil
mab
select
escap
mutant
use
individu
howev
mixtur
antibodi
could
effect
neutral
rang
mutant
virus
data
strongli
suggest
mixtur
contain
antibodi
recogn
distinct
region
target
one
step
viral
entri
like
effect
neutral
viru
suppress
gener
escap
mutant
thu
potenti
constitut
highli
effect
passiv
immunotherapi
increasingli
rna
virus
appear
respons
causal
agent
newli
emerg
infect
duffi
et
al
holm
lai
osterhau
sever
acut
respiratori
syndromecoronaviru
sarscov
one
emerg
infect
unlik
newli
emerg
zoonot
infect
sarscov
gain
abil
spread
effici
human
human
result
worldwid
outbreak
osterhau
sarscov
caus
sever
respiratori
diseas
human
result
respiratori
distress
requir
ventil
support
approxim
infect
individu
knudsen
et
al
peiri
et
al
global
outbreak
sarscov
result
infect
worldwid
baker
knudsen
et
al
ksizek
et
al
kuiken
et
al
marra
et
al
although
outbreak
recur
presenc
sarscov
environment
reservoir
remain
threat
human
health
lau
et
al
normil
therefor
import
establish
therapeut
intervent
potenti
life
threaten
infect
sarscov
caus
acut
infect
therefor
therapi
offer
instantan
protect
like
effect
number
therapeut
strategi
inhibit
viral
entri
viral
replic
viral
matur
investig
golda
pyrc
osterhau
amongst
inhibit
viral
entri
particularli
attract
sinc
protect
target
cell
infect
therebi
reduc
viral
load
allow
host
immun
system
suffici
time
mount
effect
immun
respons
clear
viru
sarscov
mediat
viral
entri
protein
unlik
human
protein
sarscov
cleav
domain
howev
distinct
domain
mediat
receptor
bind
amino
acid
region
within
repres
receptor
bind
domain
rbd
interact
cellular
receptor
angiotensinconvert
enzym
li
et
al
wong
et
al
domain
mediat
fusion
viral
host
membran
requir
releas
viral
genom
cell
ingallinella
et
al
li
et
al
rota
et
al
tripet
et
al
wong
et
al
sinc
bind
fusion
event
mediat
protein
mab
recogn
protein
may
inhibit
either
step
previous
gener
larg
panel
human
monoclon
antibodi
use
b
cell
xenomous
immun
sarscov
protein
coughlin
et
al
identifi
sever
epitop
recogn
specif
mab
found
major
neutral
antibodi
react
rbd
rbd
specif
antibodi
design
group
base
epitop
map
subgroup
base
antibodi
complementari
determin
region
sequenc
coughlin
et
al
demonstr
group
monoclon
antibodi
mab
neutral
sarscov
prevent
associ
protein
receptor
surfac
target
cell
region
upstream
rbd
well
epitop
within
domain
coughlin
et
al
duan
et
al
huang
et
al
keng
et
al
also
elicit
neutral
antibodi
context
identifi
one
mab
bind
upstream
sarscov
rbd
amino
acid
coughlin
et
al
demonstr
mab
neutral
viru
prevent
postbind
step
viral
entri
furthermor
show
combin
antibodi
effect
individu
antibodi
neutral
wild
type
well
mutant
virus
select
presenc
individu
mab
data
suggest
target
one
epitop
step
viral
entri
like
confer
better
protect
sarscov
previous
produc
human
monoclon
antibodi
mab
effect
neutral
sarscov
infect
interact
two
distinct
region
within
domain
protein
coughlin
et
al
order
understand
underli
mechan
neutral
antibodi
develop
receptor
bind
inhibit
assay
use
cell
natur
express
receptor
surfac
wong
et
al
recombin
protein
fragment
repres
amino
acid
carri
human
fc
tag
bound
surfac
target
cell
optim
concentr
maxim
bind
recombin
protein
detect
upon
stain
fitc
conjug
antihuman
igg
antibodi
use
flow
cytometri
recombin
protein
preincub
increas
concentr
previous
identifi
character
specif
mab
coughlin
et
al
bind
protein
presenc
mab
determin
compar
maxim
bind
ic
valu
mab
determin
inhibit
curv
gener
increas
concentr
mab
tabl
cell
alon
cell
lack
cellular
receptor
cell
mix
bind
fragment
well
isotyp
control
antibodi
includ
neg
control
determin
nonspecif
bind
nonspecif
inhibit
nonspecif
bind
nonspecif
inhibit
occur
fig
repres
data
obtain
group
neutral
mab
shown
fig
maximum
inhibit
bind
seen
highest
concentr
antibodi
use
fig
although
group
mab
bind
within
rbd
base
complimentari
determin
region
sequenc
group
variou
subgroup
eg
group
antibodi
like
recogn
seven
distinct
epitop
within
rbd
abl
inhibit
bind
tabl
mab
alon
fail
bind
significantli
cell
data
shown
eighteen
previous
identifi
mab
effici
prevent
bind
protein
therebi
indic
mechan
neutral
sarscov
infect
cell
antibodi
primarili
inhibit
viru
attach
tabl
fig
mab
recogn
epitop
upstream
rbd
inhibit
postbind
event
limit
epitop
map
previous
identifi
group
mab
bind
upstream
rbd
tabl
coughlin
et
al
therefor
investig
mechan
action
uniqu
mab
rbd
specif
mab
could
inhibit
receptor
associ
protein
mab
fail
block
interact
protein
cellular
receptor
fig
fact
antibodi
margin
enhanc
effect
bind
protein
cell
surfac
fig
sinc
mab
could
inhibit
bind
protein
abil
mab
disrupt
postbind
step
viral
entri
examin
use
pseudotyp
viru
express
sarscov
protein
surfac
huang
et
al
simmon
et
al
yang
et
al
yi
et
al
postbind
event
detect
bind
pseudoviru
surfac
target
cell
transient
transfect
h
allow
viral
attach
entri
follow
bind
pseudoviru
cell
treat
increas
concentr
mab
incub
overnight
mab
could
effici
prevent
viral
entri
target
cell
ad
postpseudoviru
bind
fig
furthermor
postbind
inhibit
seen
significantli
greater
observ
mab
pseudoviru
preincub
prior
addit
target
cell
p
next
investig
whether
mixtur
antibodi
react
distinct
epitop
neutral
viru
differ
mechan
lead
greater
inhibit
mab
use
combin
repres
rbd
specif
mab
group
coughlin
et
al
use
mab
mixtur
consist
two
mab
result
greater
inhibit
pseudotyp
viru
entri
mab
test
alon
fig
combin
mab
show
littl
inhibit
viru
hiv
core
pseudotyp
vsv
g
protein
hivvsvg
data
shown
indic
specif
action
mab
combin
result
dramat
inhibit
shown
signific
addit
effect
two
highest
concentr
mab
use
p
valu
tabl
group
mab
bind
region
fig
anoth
combin
consist
demonstr
increas
inhibit
p
valu
fig
combin
mab
demonstr
signific
increas
inhibit
p
valu
individu
compar
combin
mab
use
individu
compar
combin
equal
respect
compar
inhibit
seen
antibodi
test
alon
highest
concentr
fig
mab
show
enhanc
inhibit
use
combin
compar
inhibit
seen
use
individu
fig
cocktail
contain
mab
test
abil
neutral
sarscov
urbani
viral
infect
cell
briefli
sarscov
preincub
combin
mab
h
viru
antibodi
mixtur
ad
cell
cell
viabil
measur
h
later
similar
result
obtain
use
pseudotyp
viru
combin
result
significantli
increas
protect
antibodi
use
fig
abil
rbd
specif
human
mab
group
inhibit
receptor
associ
protein
detect
use
receptor
bind
inhibit
assay
repres
member
shown
group
mab
recombin
protein
preincub
increas
dilut
mab
mixtur
ad
target
cell
recombin
protein
bind
detect
flow
cytometri
follow
stain
fitclabel
antihuman
igg
b
comparison
abil
ntermin
specif
mab
rbd
specif
mab
inhibit
receptor
associ
protein
inhibit
receptor
associ
examin
describ
group
mab
isotyp
human
igg
isotyp
control
rockx
et
al
sui
et
al
sui
et
al
yang
et
al
therefor
test
abil
eleven
mab
yield
escap
mutant
cultiv
viru
presenc
nine
eleven
mab
result
emerg
escap
mutant
differ
passag
passag
viru
presenc
three
mab
result
emerg
escap
viru
within
first
sever
passag
tabl
perhap
mutant
could
escap
neutral
exist
within
viral
popul
mutat
occur
earli
viru
replic
exist
escap
mutant
confirm
grow
viru
presenc
higher
dose
correspond
mab
tabl
mab
result
gener
escap
mutant
sever
passag
mab
except
mab
result
escap
viru
observ
subneutr
concentr
tabl
virus
grown
presenc
either
yield
escap
mutant
concentr
throughout
nine
passag
suggest
possibl
recognit
conservedessenti
region
within
domain
antibodi
tabl
abil
mab
inhibit
sarscov
escap
variant
sarscov
sarscov
respect
gener
earli
passag
analyz
use
mab
sarscov
sarscov
could
effect
neutral
mixtur
mab
consist
fig
b
respect
interestingli
mab
could
moder
neutral
sarscov
effici
neutral
sarscov
use
individu
data
shown
similarli
mab
mab
could
effici
neutral
sarscov
sarscov
infect
mab
analyz
abil
neutral
sarscov
urbani
infect
cell
mab
alon
combin
preincub
sarscov
urbani
h
ad
cell
infect
measur
result
cell
death
use
luciferas
base
cell
titerglo
assay
error
bar
repres
standard
deviat
duplic
within
experi
tabl
sarscov
urbani
passag
everi
h
presenc
mab
concentr
abil
mab
gener
escap
mutant
determin
cpe
respect
data
shown
contrast
escap
variant
effect
neutral
respect
mab
use
gener
variant
fig
result
show
despit
propens
viru
escap
neutral
mab
use
individu
escap
mutant
virus
effect
neutral
mixtur
antibodi
studi
sought
understand
mechan
previous
describ
coughlin
et
al
mab
mediat
neutral
sarscov
propens
subset
mab
gener
escap
mutant
efficaci
neutral
escap
variant
mixtur
monoclon
antibodi
expect
mechan
neutral
mab
inhibit
receptor
bind
prevent
viral
attach
target
cell
observ
consist
made
investig
rockx
et
al
sui
et
al
mab
bind
upstream
rbd
amino
acid
signific
effect
viral
attach
target
cell
inhibit
postbind
event
prevent
viral
entri
recent
neutral
antibodi
nab
gener
nonimmun
scfv
librari
also
found
inhibit
rbd
bind
sui
et
al
howev
unlik
antibodi
recogn
epitop
within
rbd
nab
demonstr
broader
abil
bind
protein
variant
albeit
weak
neutral
abil
sui
et
al
mechan
inhibit
nab
yet
known
lower
effici
like
consequ
select
antibodi
librari
gener
use
nonimmun
cell
therefor
nab
may
undergon
affin
matur
result
immun
mab
describ
first
exampl
antibodi
bind
within
nterminu
protein
neutral
sarscov
inhibit
postbind
event
necessari
viral
entri
although
function
ntermin
region
domain
clearli
defin
role
region
mediat
dimer
protein
suggest
tian
et
al
xiao
et
al
addit
delet
first
amino
acid
protein
lead
loss
abil
mediat
fusion
retain
bind
tian
et
al
xiao
et
al
abil
mab
effici
inhibit
viral
entri
ad
post
viru
bind
suggest
protein
might
undergo
conform
chang
follow
bind
lead
unmask
epitop
recogn
antibodi
result
support
notion
nterminu
protein
contribut
conform
chang
requir
mediat
fusion
viral
host
membran
protein
cleavag
within
endosom
cathepsin
l
essenti
initi
fusion
viral
endosom
membran
bosch
et
al
huang
et
al
simmon
et
al
cathepsin
l
cleav
amino
acid
locat
within
junction
domain
bosch
et
al
protein
studi
suggest
conform
chang
necessari
protein
cleavag
cathepsin
l
simmon
et
al
although
definit
proof
yet
gener
possibl
mab
could
prevent
conform
chang
necessari
protein
cleavag
cathepsin
specul
support
earlier
demonstr
inhibit
phdepend
fusion
process
within
endosom
influenza
viru
west
nile
viru
viral
neutral
antibodi
block
viral
attach
imai
et
al
thompson
et
al
west
nile
viru
opson
fusion
inhibitori
antibodi
result
retent
viru
endosom
like
led
target
destruct
viru
particl
lysosom
compart
cell
thompson
et
al
studi
suggest
mab
specif
inhibit
cathepsin
cleavag
specif
viral
glycoprotein
may
serv
novel
therapi
virus
includ
ebola
viru
reoviru
human
similar
result
obtain
use
combin
mab
therapi
hbv
rsv
combin
two
mab
target
differ
epitop
within
protein
sarscov
also
addit
effect
marasco
use
mab
anoth
mab
result
increas
inhibit
import
note
combin
mab
confer
near
complet
protect
antibodi
concentr
individu
antibodi
requir
fig
howev
true
mab
combin
mab
mab
previous
determin
bind
upstream
rbd
howev
subsequ
analysi
determin
purifi
mab
fact
bind
rbd
lack
synergist
effect
indic
mab
like
interact
close
posit
conform
epitop
compet
bind
similarli
combin
rbd
specif
mab
confer
protect
senesc
mice
sarscov
challeng
howev
combin
effici
antibodi
administ
individu
indic
antibodi
possibl
compet
bind
region
rockx
et
al
observ
highlight
import
care
select
differ
mab
form
therapeut
cocktail
sarscov
rna
viru
therefor
greater
intrins
abil
gener
escap
mutant
confer
error
prone
rna
neutral
abil
mab
combin
determin
analysi
cell
viabil
use
luciferas
base
cell
titerglo
assay
h
postinfect
sarscov
use
neutral
assay
group
group
mab
combin
b
sarscov
use
neutral
assay
mab
group
combin
mab
singl
outlier
b
includ
analysi
depend
rna
polymeras
escap
mutant
gener
rapidli
presenc
high
concentr
three
mab
suggest
within
viral
popul
antigen
variant
exist
escap
mab
neutral
although
sever
mab
readili
give
rise
escap
mutant
escap
variant
appear
presenc
suboptim
concentr
mab
suggest
escap
mutant
like
gener
respons
mab
pressur
escap
mutant
gener
studi
yet
sequenc
howev
nucleic
acid
sequenc
escap
mutant
studi
reveal
singl
point
mutat
confer
resist
select
antibodi
mitsuki
et
al
sui
et
al
ter
meulen
et
al
would
interest
determin
three
dimension
structur
protein
mutant
virus
antibodi
use
select
relat
mutat
induc
chang
conform
protein
affect
bind
select
antibodi
although
viru
grown
presenc
monoclon
antibodi
could
rapidli
yield
escap
mutant
mixtur
three
mab
effect
neutral
escap
variant
mab
could
neutral
sarscov
sarscov
escap
variant
confirm
previou
find
epitop
distinct
epitop
addit
mab
could
neutral
sarscov
confirm
two
epitop
also
distinct
coughlin
et
al
howev
propens
antibodi
allow
escap
mutant
aris
use
alon
preclud
individu
therapeut
util
ideal
passiv
therapi
elimin
minim
appear
escap
variant
context
import
note
presenc
mab
escap
mutant
fail
aris
suggest
chang
epitop
might
detriment
sarscov
examin
epitop
may
result
identif
region
within
protein
would
like
good
candid
subunit
vaccin
although
other
demonstr
util
mab
cocktail
consist
antibodi
similar
mechan
action
rockx
et
al
rockx
et
al
sui
et
al
yang
et
al
present
studi
show
util
cocktail
antibodi
differ
bind
specif
also
mode
action
type
cocktail
like
neutral
broader
rang
variant
may
circul
natur
suppress
appear
escap
mutant
sarscov
use
therapeut
sarscoronaviru
sarscov
urbani
strain
obtain
cdc
viru
propag
cell
mem
serum
free
medium
sfm
contain
lglutamin
gibco
carlsband
ca
viral
titer
determin
infect
cellswel
well
plate
serial
dilut
sarscov
h
incub
co
humidifi
incub
cell
evalu
cytopath
effect
cpe
tcid
valu
calcul
reedmuench
method
escap
viru
gener
serial
passag
viru
presenc
variou
concentr
individu
mab
see
small
aliquot
escap
viru
harvest
frozen
passag
escap
virus
sarscov
sarscov
propag
cell
presenc
respect
mab
maintain
escap
mutant
viru
supernat
harvest
h
frozen
ml
aliquot
urbani
fragment
use
examin
mab
activ
consist
amino
acid
construct
contain
signal
sequenc
human
igg
fc
tag
lack
transmembran
domain
kind
gift
dr
michael
farzan
harvard
univers
construct
transfect
cell
use
capo
method
purifi
protein
sepharos
bead
santa
cruz
biotechnolog
santa
cruz
ca
describ
previous
coughlin
et
al
increas
concentr
mab
mix
constant
concentr
purifi
recombin
protein
preincub
presenc
bsa
h
follow
preincub
proteinmab
mixtur
ad
cell
incub
h
cell
wash
two
time
bsa
recombin
protein
bound
cell
surfac
detect
flow
cytometri
follow
stain
fitclabel
antihuman
igg
bd
bioscienc
nonspecif
inhibit
evalu
use
isotyp
control
human
antibodi
zyme
laboratori
san
francisco
ca
pseudotyp
viru
gener
cotransfect
produc
cell
hiv
use
effectin
transfect
reagent
accord
manufactur
instruct
invitrogen
carlsbad
ca
pseudotyp
viru
allow
singl
round
infect
pseudotyp
viru
use
infect
target
cell
transient
transfect
express
plasmid
human
express
plasmid
kind
gift
dr
michael
farzan
hiv
pseudoviru
bound
target
cell
transient
transfect
human
h
increas
concentr
mab
ad
incub
overnight
approxim
h
subsequ
medium
replac
h
postinfect
luciferas
express
determin
cell
lyse
per
manufactur
protocol
promega
madison
wi
lysat
mix
luciferas
reagent
read
use
luminomet
simultan
also
use
standard
entri
inhibit
assay
posit
control
determin
degre
inhibit
pseudotyp
viru
entri
entri
inhibit
pseudoviru
standard
neutral
perform
preincub
pseudoviru
mab
h
pseudovirusmab
mixtur
pseudoviru
alon
ad
target
cell
transient
transfect
human
incub
overnight
approxim
h
media
replac
pseudotyp
viru
quantit
elisa
zeptometrix
buffalo
ny
follow
h
postinfect
cell
lyse
luciferas
express
determin
describ
cell
seed
well
well
plate
one
day
prior
infect
follow
day
sarscov
urbani
preincub
eleven
mab
individu
mab
concentr
h
subsequ
virusmab
mixtur
ad
cell
incub
h
follow
h
incub
cell
examin
visual
sign
cpe
viru
supernat
passag
presenc
mab
individu
concentr
h
ad
cell
plate
day
viru
supernat
passag
everi
h
total
nine
passag
cell
titerglo
luminesc
cell
viabil
assay
promega
madison
wi
use
measur
cpe
cell
accord
manufactur
recommend
assay
use
measur
neutral
capac
combin
mab
use
sarscov
urbani
briefli
sarscov
urbani
preincub
mab
alon
combin
concentr
mab
ml
standard
microneutr
assay
perform
use
cell
plate
one
day
earlier
cellswel
coughlin
et
al
follow
h
cell
viabil
measur
luminesc
output
express
rel
luciferas
unit
rlu
use
cell
titerglo
luminesc
cell
viabil
assay
similarli
escap
virus
sarscov
sarscov
preincub
combin
mab
standard
neutral
assay
describ
previous
coughlin
et
al
follow
h
cell
viabil
cell
titerglo
luminesc
cell
viabil
assay
measur
luminesc
output
express
rel
luciferas
unit
rlu
